增多实验室和Thermo Fisher扩大合作伙伴关系,使用人工智能和机器人自动化细胞治疗生产. Multiply Labs and Thermo Fisher expand partnership to automate cell therapy production using AI and robotics.

复制实验室和Thermo Fisher Scientific正在扩大他们的合作伙伴关系,将自动细胞分离技术集成到机器人制造系统中,旨在简化和扩大细胞治疗生产. Multiply Labs and Thermo Fisher Scientific are expanding their partnership to integrate automated cell separation technology into robotic manufacturing systems, aiming to streamline and scale cell therapy production. 合作的重点是减少体力劳动、改进一致性和促成端对端处理。 The collaboration focuses on reducing manual labor, improving consistency, and enabling end-to-end processing. 与此同时,利用人工智能、云基质量管理和实时数据分析的自动化平台正在推进细胞和基因疗法的制造,提高可扩展性、监管合规性和业务效率。 Meanwhile, automation platforms leveraging AI, cloud-based quality management, and real-time data analytics are advancing cell and gene therapy manufacturing, enhancing scalability, regulatory compliance, and operational efficiency. AI还被用来实时监测过程,预测偏差,提高降低费用和加速发展救生疗法的质量。 AI is also being used to monitor processes in real time, predict deviations, and improve quality—key to reducing costs and accelerating development of life-saving therapies.